BIOTRONIK Blog Explore our latest insightful interviews and articles Image Blog Stories Filter and Search Filter by year - Any -20242023202220212020 Search 46 blog articles Image Blog New German Supply Chain Act Focuses on Human Rights Biotronik’s Chief Procurement Officer Takes a Look at the New Statutory Regulations Image Blog What We Eat—Some Surprises About Our Food and Heart Health 2022 has been a surprising year at times when it comes to studies of what we eat and how it affects heart health. Although there have been numerous publications looking at this relationship this year—a few stood out to us, and they may have interesting implications for our diets. Image Blog Staying Active and Sticking to Goals With a Heart Implant Cardiac pacemaker implantations are now routine interventions. Around three million people worldwide have a pacemaker, and every year 600,000 more receive an implant. Nevertheless, the diagnosis and procedure can look challenging for patients at first— especially patients who are athletes or enjoy being active. Image Blog First BIO-LIBRA Results Pave Way for More Representative Clinical Trials After starting enrollment in 2019, Dr. Valentina Kutyifa announced the first results of the BIOTRONIK-supported BIO-LIBRA trial at the Annual Heart Rhythm Society meeting (HRS 2022). Image Blog Why We Support More Representative Trials in Cardiology Cardiovascular research has achieved a lot in the last few decades—but even today the cardiology community is discussing whether the field needs gender-specific guidelines for treating cardiovascular diseases. One of the biggest obstacles is one of the most common problems in scientific research—a simple lack of data. Image Blog Future of Resorbable Scaffolds Looks Rosier As More Data Comes In, There’s Plenty of Reasons to Be Optimistic About Scaffolds Image Blog Team Spirit Through Activity: BIOTRONIK Cyclists Hit Major Road Race After Three-Year Hiatus Continuing a company tradition that started a decade ago, BIOTRONIK employees at the company’s headquarters mounted their bicycles in early July to race through Berlin as a team during VeloCity Berlin—an event that sees teams come together for either a 60km race or a 90km race through the German capital. Image Blog Enhancing Care Strategies for ICD Patients with Atrial Fibrillation The Findings of the MATRIX Study Could Change Clinical Practice, Says Cardiac Rhythm Expert Dr. Ignasi Anguera Camos Image Blog 60 Years of Saving Lives – How the BIOTRONIK Mission Continues 2023 was a landmark year for BIOTRONIK – not simply in name or number – but in action. The company’s 60 th year of operations was a busy one for lifesaving innovations like the Amvia pacemaker and CRT-P family and Oscar catheter, to laying the groundwork for helping a whole new community of patients with the Prospera TM spinal cord stimulation system, a BIOTRONIK first. Pagination Page 1 Current page 2 Page 3 Page 4 Page 5 Page 6 Previous page ‹ Previous Next page Next › Subscribe for our News You must have JavaScript enabled to use this form. Title Select TitleMsMrMXDrProf First name Last name Role Please select your roleHealthcare ProfessionalPatient or RelativeJournalistOther Email Phone Country/Region - Select -AfghanistanAlbaniaAlgeriaAmerican SamoaAndorraAngolaAnguillaAntarcticaAntigua & BarbudaArgentinaArmeniaArubaAscension IslandAustraliaAustriaAzerbaijanBahamasBahrainBangladeshBarbadosBelarusBelgiumBelizeBeninBermudaBhutanBoliviaBosnia & HerzegovinaBotswanaBouvet IslandBrazilBritish Indian Ocean TerritoryBritish Virgin IslandsBruneiBulgariaBurkina FasoBurundiCambodiaCameroonCanadaCanary IslandsCape VerdeCaribbean NetherlandsCayman IslandsCentral African RepublicCeuta & MelillaChadChileChinaChristmas IslandClipperton IslandCocos (Keeling) IslandsColombiaComorosCongo - BrazzavilleCongo - KinshasaCook IslandsCosta RicaCroatiaCubaCuraçaoCyprusCzechiaCôte d’IvoireDenmarkDiego GarciaDjiboutiDominicaDominican RepublicEcuadorEgyptEl SalvadorEquatorial GuineaEritreaEstoniaEswatiniEthiopiaFalkland IslandsFaroe IslandsFijiFinlandFranceFrench GuianaFrench PolynesiaFrench Southern TerritoriesGabonGambiaGeorgiaGermanyGhanaGibraltarGreeceGreenlandGrenadaGuadeloupeGuamGuatemalaGuernseyGuineaGuinea-BissauGuyanaHaitiHeard & McDonald IslandsHondurasHong Kong SAR ChinaHungaryIcelandIndiaIndonesiaIranIraqIrelandIsle of ManIsraelItalyJamaicaJapanJerseyJordanKazakhstanKenyaKiribatiKosovoKuwaitKyrgyzstanLaosLatviaLebanonLesothoLiberiaLibyaLiechtensteinLithuaniaLuxembourgMacao SAR ChinaMadagascarMalawiMalaysiaMaldivesMaliMaltaMarshall IslandsMartiniqueMauritaniaMauritiusMayotteMexicoMicronesiaMoldovaMonacoMongoliaMontenegroMontserratMoroccoMozambiqueMyanmar (Burma)NamibiaNauruNepalNetherlandsNetherlands AntillesNew CaledoniaNew ZealandNicaraguaNigerNigeriaNiueNorfolk IslandNorthern Mariana IslandsNorth KoreaNorth MacedoniaNorwayOmanOutlying OceaniaPakistanPalauPalestinian TerritoriesPanamaPapua New GuineaParaguayPeruPhilippinesPitcairn IslandsPolandPortugalPuerto RicoQatarRomaniaRussiaRwandaRéunionSamoaSan MarinoSarkSaudi ArabiaSenegalSerbiaSeychellesSierra LeoneSingaporeSint MaartenSlovakiaSloveniaSolomon IslandsSomaliaSouth AfricaSouth Georgia & South Sandwich IslandsSouth KoreaSouth SudanSpainSri LankaSt. BarthélemySt. HelenaSt. Kitts & NevisSt. LuciaSt. MartinSt. Pierre & MiquelonSt. Vincent & GrenadinesSudanSurinameSvalbard & Jan MayenSwedenSwitzerlandSyriaSão Tomé & PríncipeTaiwanTajikistanTanzaniaThailandTimor-LesteTogoTokelauTongaTrinidad & TobagoTristan da CunhaTunisiaTurkmenistanTurks & Caicos IslandsTuvaluTürkiyeU.S. Outlying IslandsU.S. Virgin IslandsUgandaUkraineUnited Arab EmiratesUnited KingdomUnited StatesUruguayUzbekistanVanuatuVatican CityVenezuelaVietnamWallis & FutunaWestern SaharaYemenZambiaZimbabweÅland Islands Topic Please select a topicProductsPatientsHealthcare Professionals I prefer to be contacted by Phone Email Message *Fields are mandatory. Latest Press Releases Show all press releases Image BÜLACH, Switzerland Press Release Two-Year BIOPACT Randomized Controlled Trial (RCT) Analysis Demonstrates “Persistent Excellence” for Low-Profile Passeo-18 Lux DCB BIOTRONIK announced the presentation of two-year results from the investigator-initiated BIOPACT RCT by Principal Investigator Dr. Koen Deloose at the Paris Vascular Insights 2023 congress. The randomized controlled non-inferiority trial evaluated the safety and efficacy of the Passeo®-18 Lux® drug-coated balloon (DCB) catheter compared to the In.Pact Admiral DCB (Medtronic), and showed excellent results for both balloons through 24 months. 1 The prospective, multicenter, core-lab adjudicated non-inferiority trial enrolled 302 patients in Austria, Belgium, France and Switzerland with Image AMSTERDAM, The Netherlands Press Release 12-Month-Data of BIOFLOW-DAPT Study Show Positive Results for Orsiro Mission DES With Short DAPT BIOFLOW-DAPT one-year-data demonstrated non-inferiority and a good safety profile for the Orsiro ® Mission drug-eluting stent (DES) compared to Resolute Onyx DES (p<0.0001) in patients at high risk of bleeding receiving short dual antiplatelet therapy (DAPT). Prof. Marco Valgimigli presented the novel data in a late-breaking trial session at the European Society of Cardiology’s (ESC) Congress in Amsterdam. The results were published simultaneously in Circulation. BIOFLOW-DAPT is a prospective, multi-center, international, two-arm randomized controlled clinical study to assess the safety of one Image BERLIN, Germany Press Release First Implant of Amvia Sky in Europe, the World’s First Pacemaker Approved for LBBAP* The first implant in Europe of BIOTRONIK’s latest pacemaker and CRT-P generation was conducted in early August by Prof. Dr. Jan De Pooter at the University Hospital Ghent in Belgium. The patient who received an Amvia Sky dual chamber pacemaker device was a 68-year-old man suffering from paroxysmal AV-block strongly limiting his physical efforts. “The implantation went on straightforward and very smoothly,” commented Prof. De Pooter after the procedure. “LBBAP enables pacing in a very natural, physiological way, benefiting the patient by offering physiological pacing and minimizing the risk for Press Contact Corporate Public Relations & Communications press@biotronik.com +49 (0) 30 68905 1414 Get in contact
Image Blog New German Supply Chain Act Focuses on Human Rights Biotronik’s Chief Procurement Officer Takes a Look at the New Statutory Regulations
Image Blog New German Supply Chain Act Focuses on Human Rights Biotronik’s Chief Procurement Officer Takes a Look at the New Statutory Regulations
Image Blog What We Eat—Some Surprises About Our Food and Heart Health 2022 has been a surprising year at times when it comes to studies of what we eat and how it affects heart health. Although there have been numerous publications looking at this relationship this year—a few stood out to us, and they may have interesting implications for our diets.
Image Blog What We Eat—Some Surprises About Our Food and Heart Health 2022 has been a surprising year at times when it comes to studies of what we eat and how it affects heart health. Although there have been numerous publications looking at this relationship this year—a few stood out to us, and they may have interesting implications for our diets.
Image Blog Staying Active and Sticking to Goals With a Heart Implant Cardiac pacemaker implantations are now routine interventions. Around three million people worldwide have a pacemaker, and every year 600,000 more receive an implant. Nevertheless, the diagnosis and procedure can look challenging for patients at first— especially patients who are athletes or enjoy being active.
Image Blog Staying Active and Sticking to Goals With a Heart Implant Cardiac pacemaker implantations are now routine interventions. Around three million people worldwide have a pacemaker, and every year 600,000 more receive an implant. Nevertheless, the diagnosis and procedure can look challenging for patients at first— especially patients who are athletes or enjoy being active.
Image Blog First BIO-LIBRA Results Pave Way for More Representative Clinical Trials After starting enrollment in 2019, Dr. Valentina Kutyifa announced the first results of the BIOTRONIK-supported BIO-LIBRA trial at the Annual Heart Rhythm Society meeting (HRS 2022).
Image Blog First BIO-LIBRA Results Pave Way for More Representative Clinical Trials After starting enrollment in 2019, Dr. Valentina Kutyifa announced the first results of the BIOTRONIK-supported BIO-LIBRA trial at the Annual Heart Rhythm Society meeting (HRS 2022).
Image Blog Why We Support More Representative Trials in Cardiology Cardiovascular research has achieved a lot in the last few decades—but even today the cardiology community is discussing whether the field needs gender-specific guidelines for treating cardiovascular diseases. One of the biggest obstacles is one of the most common problems in scientific research—a simple lack of data.
Image Blog Why We Support More Representative Trials in Cardiology Cardiovascular research has achieved a lot in the last few decades—but even today the cardiology community is discussing whether the field needs gender-specific guidelines for treating cardiovascular diseases. One of the biggest obstacles is one of the most common problems in scientific research—a simple lack of data.
Image Blog Future of Resorbable Scaffolds Looks Rosier As More Data Comes In, There’s Plenty of Reasons to Be Optimistic About Scaffolds
Image Blog Future of Resorbable Scaffolds Looks Rosier As More Data Comes In, There’s Plenty of Reasons to Be Optimistic About Scaffolds
Image Blog Team Spirit Through Activity: BIOTRONIK Cyclists Hit Major Road Race After Three-Year Hiatus Continuing a company tradition that started a decade ago, BIOTRONIK employees at the company’s headquarters mounted their bicycles in early July to race through Berlin as a team during VeloCity Berlin—an event that sees teams come together for either a 60km race or a 90km race through the German capital.
Image Blog Team Spirit Through Activity: BIOTRONIK Cyclists Hit Major Road Race After Three-Year Hiatus Continuing a company tradition that started a decade ago, BIOTRONIK employees at the company’s headquarters mounted their bicycles in early July to race through Berlin as a team during VeloCity Berlin—an event that sees teams come together for either a 60km race or a 90km race through the German capital.
Image Blog Enhancing Care Strategies for ICD Patients with Atrial Fibrillation The Findings of the MATRIX Study Could Change Clinical Practice, Says Cardiac Rhythm Expert Dr. Ignasi Anguera Camos
Image Blog Enhancing Care Strategies for ICD Patients with Atrial Fibrillation The Findings of the MATRIX Study Could Change Clinical Practice, Says Cardiac Rhythm Expert Dr. Ignasi Anguera Camos
Image Blog 60 Years of Saving Lives – How the BIOTRONIK Mission Continues 2023 was a landmark year for BIOTRONIK – not simply in name or number – but in action. The company’s 60 th year of operations was a busy one for lifesaving innovations like the Amvia pacemaker and CRT-P family and Oscar catheter, to laying the groundwork for helping a whole new community of patients with the Prospera TM spinal cord stimulation system, a BIOTRONIK first.
Image Blog 60 Years of Saving Lives – How the BIOTRONIK Mission Continues 2023 was a landmark year for BIOTRONIK – not simply in name or number – but in action. The company’s 60 th year of operations was a busy one for lifesaving innovations like the Amvia pacemaker and CRT-P family and Oscar catheter, to laying the groundwork for helping a whole new community of patients with the Prospera TM spinal cord stimulation system, a BIOTRONIK first.
Image BÜLACH, Switzerland Press Release Two-Year BIOPACT Randomized Controlled Trial (RCT) Analysis Demonstrates “Persistent Excellence” for Low-Profile Passeo-18 Lux DCB BIOTRONIK announced the presentation of two-year results from the investigator-initiated BIOPACT RCT by Principal Investigator Dr. Koen Deloose at the Paris Vascular Insights 2023 congress. The randomized controlled non-inferiority trial evaluated the safety and efficacy of the Passeo®-18 Lux® drug-coated balloon (DCB) catheter compared to the In.Pact Admiral DCB (Medtronic), and showed excellent results for both balloons through 24 months. 1 The prospective, multicenter, core-lab adjudicated non-inferiority trial enrolled 302 patients in Austria, Belgium, France and Switzerland with
Image BÜLACH, Switzerland Press Release Two-Year BIOPACT Randomized Controlled Trial (RCT) Analysis Demonstrates “Persistent Excellence” for Low-Profile Passeo-18 Lux DCB BIOTRONIK announced the presentation of two-year results from the investigator-initiated BIOPACT RCT by Principal Investigator Dr. Koen Deloose at the Paris Vascular Insights 2023 congress. The randomized controlled non-inferiority trial evaluated the safety and efficacy of the Passeo®-18 Lux® drug-coated balloon (DCB) catheter compared to the In.Pact Admiral DCB (Medtronic), and showed excellent results for both balloons through 24 months. 1 The prospective, multicenter, core-lab adjudicated non-inferiority trial enrolled 302 patients in Austria, Belgium, France and Switzerland with
Image AMSTERDAM, The Netherlands Press Release 12-Month-Data of BIOFLOW-DAPT Study Show Positive Results for Orsiro Mission DES With Short DAPT BIOFLOW-DAPT one-year-data demonstrated non-inferiority and a good safety profile for the Orsiro ® Mission drug-eluting stent (DES) compared to Resolute Onyx DES (p<0.0001) in patients at high risk of bleeding receiving short dual antiplatelet therapy (DAPT). Prof. Marco Valgimigli presented the novel data in a late-breaking trial session at the European Society of Cardiology’s (ESC) Congress in Amsterdam. The results were published simultaneously in Circulation. BIOFLOW-DAPT is a prospective, multi-center, international, two-arm randomized controlled clinical study to assess the safety of one
Image AMSTERDAM, The Netherlands Press Release 12-Month-Data of BIOFLOW-DAPT Study Show Positive Results for Orsiro Mission DES With Short DAPT BIOFLOW-DAPT one-year-data demonstrated non-inferiority and a good safety profile for the Orsiro ® Mission drug-eluting stent (DES) compared to Resolute Onyx DES (p<0.0001) in patients at high risk of bleeding receiving short dual antiplatelet therapy (DAPT). Prof. Marco Valgimigli presented the novel data in a late-breaking trial session at the European Society of Cardiology’s (ESC) Congress in Amsterdam. The results were published simultaneously in Circulation. BIOFLOW-DAPT is a prospective, multi-center, international, two-arm randomized controlled clinical study to assess the safety of one
Image BERLIN, Germany Press Release First Implant of Amvia Sky in Europe, the World’s First Pacemaker Approved for LBBAP* The first implant in Europe of BIOTRONIK’s latest pacemaker and CRT-P generation was conducted in early August by Prof. Dr. Jan De Pooter at the University Hospital Ghent in Belgium. The patient who received an Amvia Sky dual chamber pacemaker device was a 68-year-old man suffering from paroxysmal AV-block strongly limiting his physical efforts. “The implantation went on straightforward and very smoothly,” commented Prof. De Pooter after the procedure. “LBBAP enables pacing in a very natural, physiological way, benefiting the patient by offering physiological pacing and minimizing the risk for
Image BERLIN, Germany Press Release First Implant of Amvia Sky in Europe, the World’s First Pacemaker Approved for LBBAP* The first implant in Europe of BIOTRONIK’s latest pacemaker and CRT-P generation was conducted in early August by Prof. Dr. Jan De Pooter at the University Hospital Ghent in Belgium. The patient who received an Amvia Sky dual chamber pacemaker device was a 68-year-old man suffering from paroxysmal AV-block strongly limiting his physical efforts. “The implantation went on straightforward and very smoothly,” commented Prof. De Pooter after the procedure. “LBBAP enables pacing in a very natural, physiological way, benefiting the patient by offering physiological pacing and minimizing the risk for